92 results about "Aminomethylbenzoic acid" patented technology

The invention provides a medical sodium alginate gel microsphere and a preparation method and application of the medical sodium alginate gel microsphere. The medical sodium alginate gel microsphere consists of a composite medicine carrier and a water-insoluble medicine; the medicine is coated with the composite medicine carrier; and the composite medicine carrier is an ion crosslinking agent-sodium alginate-divalent metal ion, wherein the ion crosslinking agent is 4-aminomethylbenzoic acid or tranexamic acid. The preparation method comprises the following steps of: (1) mixing ion crosslinking agent aqueous solution with divalent metal ion solution in the same volume to obtain composite solidifying liquid; (2) dispersing medicine powder or an agent into sodium alginate aqueous solution; uniformly mixing; dropwise adding the mixture into the composite solidifying liquid obtained in step (1) through a high-voltage static droplet generating device or a syringe needle, so that the mixture drops are solidified into spheres; and (3) dehydrating gel microspheres which are washed with the distilled water; and drying at normal temperature. The medical sodium alginate gel microsphere can be used for treating tuberculosis, endocrine disease and tumor, and also can be used for treating local acute hemorrhage and chronic errhysis.

To provide a novel packing material for liquid chromatography capable of separating and purifying, or collecting and recovering, a biopolymer such as a protein or a peptide by adsorption and desorption by a pH change without being influenced by the isoelectric point of the protein or by the salt concentration in a solvent in which the biopolymer such as the protein is dissolved, and to provide a process for concentrating and recovering a desired biopolymer such as a protein or a peptide from a large amount of dilute cell culture solution by means of such a packing material. Separation and purification, or collection and recovery, of a biopolymer, is carried out by liquid chromatography by means of a packing material for liquid chromatography comprising a base matrix and a ligand immobilized to the base matrix, wherein the base matrix is a hydrophilic base matrix having alcoholic hydroxy groups on its surface, the ligand is at least one ligand selected from the group consisting of an +--amino acid represented by the following formula (1): RCH(NH 2 )COOH (1) wherein R is an aromatic group or a C 5-7 non-ionic aliphatic group, and an aminomethyl benzoic acid, and the ligand is immobilized to the base matrix by an amide bond or an urethane bond via the amino group contained in the compound represented by the formula (1).

The invention discloses an aminomethylbenzoic acid sample impurity detection device which comprises a liquid chromatograph, a weighing feeding machine, a mixed quantitative conveying bottle and a simple substance quantitative conveying bottle, wherein the weighing feeding machine consists of an aminomethylbenzoic acid sample weighing feeding machine, a monosodium phosphate weighing feeding machine, a lauryl sodium sulfate weighing feeding machine, a methyl benzoic acid weighing feeding machine and a p-chloromethyl benzoic acid weighing feeding machine. The weighing is all performed in a quantitative manner, the weighing accuracy is improved, the errors are reduced, the measurement accuracy is improved, measurement errors caused by artificial factors are avoided, qualitative and quantitative analysis is achieved, and the repeatability is good.

The invention provides a preparation method of 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzoic acid. The preparation method comprises the following steps of: carrying out a guanidine-forming reaction on 3-amino-4-methyl toluic acid and cyanamide under the acidic condition of hydrochloric acid to generate 3-[(aminoiminomethyl)amino]-4-methyl-benzoic acid-hydrochloride, and then carrying out a cyclization reaction on the 3-amino-4-methyl toluic acid and cyanamide and 3-(dimethylamino)-1-(3-pyridyl)-2-propylene-1-one to generate the 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzoic acid, wherein a structural formula of the 3-[(aminoiminomethyl)amino]-4-methyl-benzoic acid-hydrochloride is shown as the description. The method has short route, simple operation, safe and environmentally-friendly process, repeatability, low cost, high yield, high stability and safety of a guanidine hydrochloride intermediate, suitability for large-scale industrial production and higher economic benefit and social benefit.

The invention discloses a care medicine composition used before operative anesthesia and a preparation method thereof. The medicine composition is composed of Chinese herbal medicinal ingredients and Western medicinal ingredients. The Chinese herbal medicinal ingredients mainly comprise fruits of Celastrus rosthornianus Loes, sow thistle flower and seeds, rhapis excelsa, the root of Laxleaf Beautifulflower Millettia, all-grass of auriculate dichrocephala, pine among the Indian Bread, fructus terminaliae billericae, aizoon stonecrop herb, valerian, sandalwood extract and crowndaisy chrysanthemum extract. The Western medicinal ingredients mainly comprise aminomethylbenzoic acid, diaminocaproic acid, taurine and cefuroxime. The care medicine composition is scientifically matched according to different medicine effects and characteristics of Chinese and western medicine, is applied to according to indications, has the effects of soothing nerves and calming heart, relieving pain and removing swelling, resisting bacteria and diminishing inflammation, stopping bleeding, enhancing human body immunocompetence and resisting virus infection, and effectively eases preoperative tension, anxiety, fear and other psychic reactions of a patient. The care medicine composition used before operative anesthesia is simple in preparation technology, remarkable in treatment effect and gentle in medicine effect and has the good medical value.

To provide an amidite for nucleic acid synthesis, which enables a protective group therein to be removed under moderate conditions and can be practically used, and a nucleic acid synthesizing method using the amidite for nucleic acid synthesis. Specifically, the present invention relates to an amidite for nucleic acid synthesis represented by General Formula (I) below, and a nucleic acid synthesizing method using the amidite for nucleic acid synthesis:where X denotes a base; Y denotes a protective group formed of any one of a 4-aminobutyric acid derivative, an o-aminomethylbenzoic acid derivative, an o-aminophenylacetic acid derivative, an o-aminoethylbenzoic acid derivative, an o-aminomethylphenylacetic acid derivative, an o-aminophenylpropionic acid derivative and a 5-aminovaleric acid derivative; and Q denotes one of a hydrogen atom and a hydroxyl group.

The invention relates to a method for preparing tranexamicacid. The method comprises the following steps: adding the aminomethylbenzoic acid, water, concentrated sulfuric acid and a catalyst into a reaction vessel for stirring and heating; then introducing hydrogen for carrying out hydrogenation reaction to obtain hydrogenated reaction liquid; adding the hydrogenated reaction liquid and the concentrated sulfuric acid into the reaction vessel, raising the temperature to 180 to 200 DEG C, and carrying out heat-preservation stirring and conversion reaction to obtain the tranexamicacid. The methodfor preparing the tranexamicacid, disclosed by the invention, has the advantages of simplified technology, short reaction time and high synthesis efficiency.

The invention belongs to the technical field of medicines, discloses a pharmaceutical composition of tranexamic acid, and particularly relates to a pharmaceutical composition containing tranexamic acid and organic acid. The pharmaceutical composition can be prepared into injection; the high-temperature and high-light tests show that the impurities, namely, cycloolefin, aminomethylbenzoic acid and a Z-isomer, and the total impurities of the injection meet the quality requirements. A preparation prepared from the pharmaceutical composition has the advantages of high stability and low impurity content.

The invention discloses an aminomethylbenzoic acid sodium chloride injection and a preparation method thereof. Raw materials of the injection are composed of: 5-7 kg of aminomethylbenzoic acid, 26-28kg of sodium chloride, 1.1-1.3 kg of activated carbon, and water for injection and the total being 3000000 ml. The invention provides the stable and safe aminomethylbenzoic acid sodium chloride injection, solves the technical problem that aminomethylbenzoic acid sodium chloride is stable and sensitive to light, and provides the safe aminomethylbenzoic acid sodium chloride injection for a clinicalapplication.

The invention discloses a tranexamic acid preparation method, and belongs to the technical field of drug synthesis. The preparation method includes the steps: (1) mixing aminomethylbenzoic acid and pure water, slowly adding concentrated sulfuric acid under the condition of stirring, heating mixture to preset temperature and performing cooling crystallization and filtration to obtain pretreated aminomethylbenzoic acid; (2) adding sulfuric acid solution and catalysts, performing hydrogenation reaction on the pretreated aminomethylbenzoic acid and removing residual sulfuric acid to obtain a hydrogenated product; (3) adding alkali and the pure water into the hydrogenated product, controlling the weight ratio of the hydrogenated product to the alkali to be 1:(3-6), heating the mixture to set temperature, and performing transposition reaction on the hydrogenated product to obtain tranexamic acid. According to the tranexamic acid preparation method, the aminomethylbenzoic acid is pretreated to decrease the content of organic amine and ferrum in raw materials, the service life of the catalysts is prolonged, and production cost is greatly reduced. The adding proportion of the alkali is properly increased, so that the proportion of trans-tranexamic acid in a transposition product, and transposition time is shortened.

In a hemostatic tranexamic acid production process, the chlorination single-pass conversion rate of p-methylbenzoic acid is normally controlled in a range of 65-70% in order to control impurity generation, which causes that 30-35% of p-methylbenzoic acid does not participate in reaction; further, impurities such as p-dichloromethyl benzoic acid are inevitably generated in a chlorination process; in an ammoniation process, di-substituted and tri-substituted side reactions are generated besides generation of p-aminomethylbenzoic acid, and thus a great quantity of solid wastes are generated, wherein by analysis, the solid wastes include 5% of p-aminomethylbenzoic acid, 13% of p-formylbenzoic acid, 35% of p-methylbenzoic acid, 28% of 4,4'-dicarboxyl dibenzylamine, 3% of 4,4',4''-tricarboxyl tribenzylamine, 11% of N-(p-aminomethylbenzoyl)-aminomethylbenzoic acid and 5% of others. The invention provides a method for converting 4,4'-dicarboxyl dibenzylamine into p-methylbenzoic acid and p-aminomethylbenzoic acid by hydrogenation debenzylation in presence of catalysts, and the recovery rate is not lower than 90%.